混合聚合数据与个体参与者数据的双阶段靶向最大似然估计及其在耐多药结核病中的应用
研究提出一种针对混合聚合数据与个体参与者数据荟萃分析的新方法,基于逆概率加权靶向最大似然估计的两阶段抽样数据改编,用于耐多药结核病治疗有效性系统评价,并通过模拟研究展示方法性质并与替代方法对比。
要点
- 方法改编自逆概率加权靶向最大似然估计,适用于两阶段抽样数据。
- 应用场景为耐多药结核病系统评价,部分研究提供个体数据,部分仅提供聚合数据。
- 关注在干预特定药物而不干预其他药物时的预期潜在结局估计。
核心结论
- 提出一种针对混合聚合数据与个体参与者数据的双阶段靶向最大似然估计方法,并将其应用于耐多药结核病治疗有效性估计。
研究设计与样本
- 方法学研究,改编逆概率加权靶向最大似然估计用于两阶段抽样数据,并通过模拟研究展示方法性质并与替代方法对比。
主要发现
- 方法通过靶向最大似然估计将估计从观察到治疗的研究转运至全目标人群,并采用第二加权成分调整缺失个体参与者数据的研究。
- 在模拟研究中展示了所提方法的性质,并与替代方法进行了对比。
- 最终将该方法应用于耐多药结核病案例研究,估计治疗有效性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this study, we develop a new method for the meta-analysis of mixed aggregate data (AD) and individual participant data (IPD). The method is an adaptation of inverse probability weighted targeted maximum likelihood estimation (IPW-TMLE), which was initially proposed for two-stage sampled data. Our methods are motivated by a systematic review investigating treatment effectiveness for multidrug resistant tuberculosis (MDR-TB) where the available data include IPD from some studies but only AD from others. One complication in this application is that participants with MDR-TB are typically treated with multiple antimicrobial agents where many such medications were not observed in all studies considered in the meta-analysis. We focus here on the estimation of the expected potential outcome while intervening on a specific medication but not intervening on any others. Our method involves the implementation of a TMLE that transports the estimation from studies where the treatment is observed to the full target population. A second weighting component adjusts for the studies with missing (inaccessible) IPD. We demonstrate the properties of the proposed method and contrast it with alternative approaches in a simulation study. We finally apply this method to estimate treatment effectiveness in the MDR-TB case study.
引用
- Siddique AA, Schnitzer ME, Balakrishnan N, et al. Two-stage targeted maximum likelihood estimation for mixed aggregate and individual participant data analysis with an application to multidrug resistant tuberculosis. Stat Med. 2023. PMID: 37985441. doi:10.1002/sim.9963
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。